Experiment 1099693
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | EDMONSON,JH: HAHN,RG: CREAGAN,ET: O'CONNELL,MJ:. (1983). PHASE 2 STUDY OF MAYTANSINE IN ADVANCED SARCOMAS.. 67(4) |
| Amount utilized | |
| Compound isolated | |
| Disease | RESULTS OF A PHASE II STUDY INVOLVING 15 PATIENTS WITH HISTOLOGICALLY CONFIRMED UNRESECTABLE METASTATIC SARCOMAS. DOSING WAS BY RAPID IV INFUSION DAILY FOR 3 CONSECTIVE DAYS EVERY 3 WEEKS. DOSES WERE MODIFIED WHEN EXCESSIVE TOXICITY WAS SEEN. NONE OF THE 15 SUBJECTS EXPERIENCED OBJECTIVE TUMOR REGRESSION AND ONLY 1 PATIENT EXPERIENCED EVEN A TRANSIENT MINOR DEGREE OF TUMOR SHRINKAGE. 6 PATIENTS DID HAVE A STABLE DISEASE FOR AT LEAST 6 WEEKS, WITH THE LONGEST CONTINUING FOR 21 WEEKS. 8 PATIENTS EXPERIENCED IMMEDIATE DISEASE PROGRESSION FOLLOWING THE INTIAL COURSE. ONLY 4 OF THE 14 PATIENTS FOR WHOM ANY TOXIC EFFECTS WERE ADEQUATELY DISCRIBED EXPERIENCED NO TOXICITY. NO PATIENT WAS REMOVED FROM THE STUDY BECAUSE OF DRUG TOXICITY AND NO MAYTANSINE RELATED DEATHS OCCURRED. MEDIAN SURVIVAL FOR THE 15 PATIENTS WHO RECEIVED MAYTANSINE WAS 117 DAYS. IT IS CONCLUDED THAT MAYTANSINE IS NOT EFFECTIVE AGAINST ADVANCED SARCOMAS. |
| Dose amount | 0.6 MG |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |